Merifin Capital

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

DoveConviene S.R.L. designs and develops a digital platform which helps people to shop by saving money through offers and leaflets presented georeferenced manner. The company was founded in 2010 and is based in Sestu, Italy. The startup trades under the brand DoveConviene in Italy and ShopFully in the U.S., as well as various other names in Spain, Brazil, Mexico and Indonesia (TechCrunch).

DoveConviene S.R.L. designs and develops a digital platform which helps people to shop by saving money through offers and leaflets presented georeferenced manner. The company was founded in 2010 and is based in Sestu, Italy. The startup trades under the brand DoveConviene in Italy and ShopFully in the U.S., as well as various other names in Spain, Brazil, Mexico and Indonesia (TechCrunch).

Launched in 2013 in France, Flayr is a unique place for shopping discoveries, allowing people to discover outsourced and crowdsourced edgy little brands and take benefit of great deals on big brands. Flayr is very user-centric, designed only to fulfill their users' every needs. Flayr is developped in Paris, Caen (yes, Caen, Normandy-based city somewhere in France is the new Palo Alto) & USA by Olivier, Nicolas, Philippe, Jerome, Pierre, Delphine, Clémence, Arnaud, Valentin, Jérôme, Antoine, Antoine, Julie, Nabil, Tiphaine, Guillaume, Julien, Isaline, Romain, David, Cassio, and Arthur. France finally found its fourth F: "Fashion, Fragrance, Fromage and Flayr"!

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

Plastic Logic Ltd specializes in the development and manufacturing of plastic electronics, particularly flexible displays. The company produces both color and monochrome electrophoretic displays, which are utilized in a variety of applications including smartphones, e-readers, tablets, signage, wristwatches, and automotive displays. With a focus on lightweight, shatterproof, and energy-efficient technology, Plastic Logic's products offer significant advantages over traditional screens. The company's manufacturing capabilities are centered in Dresden, Germany, where it operates a pioneering facility dedicated to organic electronics. It serves a diverse clientele, including OEMs, system integrators, and device manufacturers in multiple countries, including the United Kingdom, Germany, and Russia. Additionally, Plastic Logic collaborates with third-party companies through an open pilot line, providing expertise in the industrialization of flexible electronics. Founded in 2000 and based in Cambridge, Plastic Logic continues to innovate in the field of flexible display technology.

Metara manufactures chemical metrology tools for semiconductor industry that are used in monitoring and controlling chemical processes. Its products include sentry trace contamination metrology system, which monitors benign chemistries for trace contaminants; and sentry chemical composition metrology system, which monitors copper electroplating and cobalt bath chemistries. The company also offers sentry harsh chemistry metrology system, an analysis solution for harsh chemistries used in semiconductor manufacturing processes; and inline mass spectrometer, a chemical metrology solution that determines chemical composition and potential yield-or process-limiting contaminants. Metara Inc. was founded in 2000 and is headquartered in Sunnyvale, California.

DanioLabs Ltd. discovers and develops therapeutics for neurological, ophthalmologic, metabolic, and gastrointestinal diseases.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other proliferative diseases. The company is advancing several oncology programs, including CYC065, a cyclin-dependent kinase (CDK) inhibitor currently in Phase I trials for solid tumors and in combination with venetoclax for chronic lymphocytic leukemia. CYC140, a polo-like kinase inhibitor, is also in Phase I trials for advanced leukemias. Additionally, sapacitabine, an oral nucleoside analogue prodrug, is being evaluated in a Phase 1/2 combination study with seliciclib, another CDK inhibitor, for patients with BRCA mutations. Cyclacel's pipeline includes collaborations with notable institutions, such as the University of Texas MD Anderson Cancer Center, to assess the safety and efficacy of its treatments in hematological malignancies. The company was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Optiva develops and manufactures nanomaterials for use in optical, electro-optical, and semiconductor applications.